Bayer Aktiengesellschaft (BAYRY)
USD 6.75
(4.33%)
USD 6.75
(4.33%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.94 Billion EUR | -170.87% |
| 2022 | 4.15 Billion EUR | 315.0% |
| 2021 | 1 Billion EUR | 106.43% |
| 2020 | -15.56 Billion EUR | -740.37% |
| 2019 | 2.43 Billion EUR | 43.36% |
| 2018 | 1.69 Billion EUR | -47.81% |
| 2017 | 3.24 Billion EUR | -28.32% |
| 2016 | 4.53 Billion EUR | 10.24% |
| 2015 | 4.11 Billion EUR | 19.96% |
| 2014 | 3.42 Billion EUR | 7.43% |
| 2013 | 3.18 Billion EUR | 32.71% |
| 2012 | 2.4 Billion EUR | -2.71% |
| 2011 | 2.47 Billion EUR | 89.85% |
| 2010 | 1.3 Billion EUR | -4.27% |
| 2009 | 1.35 Billion EUR | -20.94% |
| 2008 | 1.71 Billion EUR | -25.46% |
| 2007 | 2.3 Billion EUR | 36.05% |
| 2006 | 1.69 Billion EUR | 6.33% |
| 2005 | 1.59 Billion EUR | 133.86% |
| 2004 | 681.61 Million EUR | -74.13% |
| 2003 | 2.63 Billion EUR | 148.39% |
| 2002 | 1.06 Billion EUR | 9.73% |
| 2001 | 966.56 Million EUR | -46.91% |
| 2000 | 1.82 Billion EUR | -9.06% |
| 1999 | 2 Billion EUR | 24.04% |
| 1998 | 1.61 Billion EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -34 Million EUR | -101.7% |
| 2024 Q1 | 2 Billion EUR | 49.59% |
| 2023 Q2 | -1.88 Billion EUR | -186.64% |
| 2023 Q4 | 1.33 Billion EUR | 129.26% |
| 2023 Q1 | 2.17 Billion EUR | 256.46% |
| 2023 Q3 | -4.56 Billion EUR | -142.13% |
| 2023 FY | -2.94 Billion EUR | -170.87% |
| 2022 FY | 4.15 Billion EUR | 315.0% |
| 2022 Q1 | 3.29 Billion EUR | 183.46% |
| 2022 Q2 | -289 Million EUR | -108.78% |
| 2022 Q3 | 546 Million EUR | 288.93% |
| 2022 Q4 | 611 Million EUR | 11.9% |
| 2021 Q4 | 1.16 Billion EUR | 1265.88% |
| 2021 Q1 | 2.08 Billion EUR | 578.25% |
| 2021 Q2 | -2.32 Billion EUR | -211.44% |
| 2021 Q3 | 85 Million EUR | 103.65% |
| 2021 FY | 1 Billion EUR | 106.43% |
| 2020 Q1 | 1.48 Billion EUR | 5614.81% |
| 2020 Q4 | 308 Million EUR | 104.0% |
| 2020 Q2 | -9.61 Billion EUR | -745.4% |
| 2020 FY | -15.56 Billion EUR | -740.37% |
| 2020 Q3 | -7.7 Billion EUR | 19.82% |
| 2019 Q1 | 1.24 Billion EUR | 131.48% |
| 2019 Q3 | 1.03 Billion EUR | 156.44% |
| 2019 FY | 2.43 Billion EUR | 43.36% |
| 2019 Q4 | -27 Million EUR | -102.61% |
| 2019 Q2 | 404 Million EUR | -67.45% |
| 2018 Q1 | 1.95 Billion EUR | 2973.53% |
| 2018 Q2 | 794 Million EUR | -59.37% |
| 2018 FY | 1.69 Billion EUR | -47.81% |
| 2018 Q3 | 2.87 Billion EUR | 261.59% |
| 2018 Q4 | -3.94 Billion EUR | -237.3% |
| 2017 Q2 | 1.22 Billion EUR | -41.24% |
| 2017 FY | 3.24 Billion EUR | -28.32% |
| 2017 Q3 | 773 Million EUR | -36.85% |
| 2017 Q1 | 2.08 Billion EUR | 359.82% |
| 2017 Q4 | -68 Million EUR | -108.8% |
| 2016 Q1 | 1.51 Billion EUR | 146.49% |
| 2016 FY | 4.53 Billion EUR | 10.24% |
| 2016 Q2 | 1.38 Billion EUR | -8.67% |
| 2016 Q3 | 1.18 Billion EUR | -13.99% |
| 2016 Q4 | 453 Million EUR | -61.84% |
| 2015 Q2 | 1.16 Billion EUR | -12.74% |
| 2015 Q3 | 999 Million EUR | -14.18% |
| 2015 FY | 4.11 Billion EUR | 19.96% |
| 2015 Q1 | 1.33 Billion EUR | 495.54% |
| 2015 Q4 | 613 Million EUR | -38.64% |
| 2014 FY | 3.42 Billion EUR | 7.43% |
| 2014 Q2 | 953 Million EUR | -33.03% |
| 2014 Q1 | 1.42 Billion EUR | 212.75% |
| 2014 Q4 | 224 Million EUR | -72.88% |
| 2014 Q3 | 826 Million EUR | -13.33% |
| 2013 Q1 | 1.16 Billion EUR | 210.16% |
| 2013 Q3 | 733 Million EUR | -12.84% |
| 2013 Q4 | 455 Million EUR | -37.93% |
| 2013 Q2 | 841 Million EUR | -27.5% |
| 2013 FY | 3.18 Billion EUR | 32.71% |
| 2012 Q3 | 516 Million EUR | 7.28% |
| 2012 Q1 | 1.04 Billion EUR | 161.96% |
| 2012 Q4 | 374 Million EUR | -27.52% |
| 2012 FY | 2.4 Billion EUR | -2.71% |
| 2012 Q2 | 481 Million EUR | -53.75% |
| 2011 Q3 | 642 Million EUR | -14.06% |
| 2011 FY | 2.47 Billion EUR | 89.85% |
| 2011 Q4 | 397 Million EUR | -38.16% |
| 2011 Q1 | 684 Million EUR | 454.4% |
| 2011 Q2 | 747 Million EUR | 9.21% |
| 2010 FY | 1.3 Billion EUR | -4.27% |
| 2010 Q3 | 285 Million EUR | -46.23% |
| 2010 Q1 | 631 Million EUR | 312.42% |
| 2010 Q2 | 530 Million EUR | -16.01% |
| 2010 Q4 | -193 Million EUR | -167.72% |
| 2009 Q1 | 425 Million EUR | 300.94% |
| 2009 FY | 1.35 Billion EUR | -20.94% |
| 2009 Q2 | 532 Million EUR | 25.18% |
| 2009 Q4 | 153 Million EUR | -38.55% |
| 2009 Q3 | 249 Million EUR | -53.2% |
| 2008 Q1 | 762 Million EUR | 1037.31% |
| 2008 Q4 | 106 Million EUR | -61.73% |
| 2008 Q3 | 277 Million EUR | -51.74% |
| 2008 Q2 | 574 Million EUR | -24.67% |
| 2008 FY | 1.71 Billion EUR | -25.46% |
| 2007 Q4 | 67 Million EUR | -94.3% |
| 2007 Q2 | 412.97 Million EUR | -37.02% |
| 2007 Q1 | 655.73 Million EUR | 180.55% |
| 2007 FY | 2.3 Billion EUR | 36.05% |
| 2007 Q3 | 1.17 Billion EUR | 184.52% |
| 2006 Q4 | 233.73 Million EUR | -26.94% |
| 2006 FY | 1.69 Billion EUR | 6.33% |
| 2006 Q3 | 319.91 Million EUR | -29.28% |
| 2006 Q1 | 599.78 Million EUR | 2296.78% |
| 2006 Q2 | 452.34 Million EUR | -24.58% |
| 2005 Q2 | 148.66 Million EUR | -77.19% |
| 2005 Q1 | 651.85 Million EUR | 1507.04% |
| 2005 Q3 | 492.06 Million EUR | 230.98% |
| 2005 FY | 1.59 Billion EUR | 133.86% |
| 2005 Q4 | 25.02 Million EUR | -94.91% |
| 2004 Q1 | 399.33 Million EUR | -80.47% |
| 2004 Q2 | 127.89 Million EUR | -67.97% |
| 2004 Q3 | 21.71 Million EUR | -83.02% |
| 2004 FY | 681.61 Million EUR | -74.13% |
| 2004 Q4 | 40.56 Million EUR | 86.81% |
| 2003 Q3 | -122.67 Million EUR | -196.02% |
| 2003 FY | 2.63 Billion EUR | 148.39% |
| 2003 Q1 | 584.84 Million EUR | 243.74% |
| 2003 Q2 | 127.75 Million EUR | -78.16% |
| 2003 Q4 | 2.04 Billion EUR | 1766.54% |
| 2002 FY | 1.06 Billion EUR | 9.73% |
| 2002 Q4 | -406.86 Million EUR | -162.1% |
| 2002 Q3 | 655.19 Million EUR | 227.08% |
| 2002 Q1 | 522.02 Million EUR | 636.91% |
| 2002 Q2 | 200.31 Million EUR | -61.63% |
| 2001 Q2 | 563.59 Million EUR | 27.57% |
| 2001 FY | 966.56 Million EUR | -46.91% |
| 2001 Q4 | 70.83 Million EUR | 135.65% |
| 2001 Q3 | -198.68 Million EUR | -135.25% |
| 2001 Q1 | 441.77 Million EUR | 0.0% |
| 2000 FY | 1.82 Billion EUR | -9.06% |
| 1999 FY | 2 Billion EUR | 24.04% |
| 1998 FY | 1.61 Billion EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | 149.387% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | 136.648% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | 453.947% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | -5104.204% |
| Novartis AG | 14.85 Billion USD | 119.805% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | 1736.566% |